Circulating cytokine levels in prostate cancer patients undergoing radiation therapy: Influence of neoadjuvant total androgen suppression

In Vivo

Volumn 23, Issue 5, 2009, Pages 827-833

  Johnke, Roberta M ^a   Edwards, Judy M ^a   Evans, Mark J ^a   Nangami, Gladys N ^a   Bakken, Nicholas T G ^a   Kilburn, Jeremy M ^a   Lee, Tung Kwang ^a   Allison, Ron R ^a   Karlsson, Ulf L ^a   Arastu, Hyder H ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Antiandrogen therapy; Cytokines; Prostate cancer; Radiotherapy

Indexed keywords

CYTOKINE; FLUTAMIDE; GOSERELIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CYTOKINE PRODUCTION; EARLY CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MALE; PROSTATE CANCER;

EID: 70350044959     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Anscher MS, Murase T, Prescott DM, Marks, LB, Reisenbichler H, Bentel GC, Spencer D, Sherouse G and Jirtle RL: Changes in plasma TGF beta levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis. Int J Radiat Oncol Biol Phys 30: 671-676, 1994. (Pubitemid 2159469)
2. Chen Y, Williams J, Ding J, Hernady E, Liu W and Smudzin T: Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol 12(Suppl): 26-33, 2002. (Pubitemid 34246065)
3. Hallahan DE, Haimovitz-Friedman A, Kufe DW, Fuks Z and Weichselbaum RR: The role of cytokines in radiation oncology. In: Important Advances in Oncology. DeVita VT, Hellman S and Rosenberg SA (eds.). Philadelphia, JB Lippincot, pp. 71-80, 1993.
4. Rubin P, Johnston CJ, Williams JP, McDonald S and Finkelstein JN: A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 33: 99-109, 1995.
5. Anscher MS, Peters WP, Reisenbichler H, Petros WP and Jirtle RL: Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 328: 1592-1598, 1993. (Pubitemid 23151919)
6. Anscher MS, Kong-KM, Murase T and Jirtle R: Normal tissue injury after cancer therapy is a local response exacerbated by an endocrine effect of TGFβ. Brit J Radiol 68: 331-333, 1995.
7. Chen Y, Rubin P, Williams J, Hernady E, Smudzin T and Okunieff P: Circulating IL-6 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 4: 641-648, 2001. (Pubitemid 32112192)
8. Gridley DS, Slater JD, Yonemoto LT, Miller DW, Rossi C, Archambeau JO, Andres ML, Oey M and Slater JM: Pilot study of cytokine profiles in prostate cancer patients undergoing proton or conventional radiotherapy. Int J Oncol 8: 175-181, 1996.
9. Fleckenstein K, Gauter-Fleckenstein B, Jackson IL, Rabbani Z, Anscher M and Vujaskovic Z: Using biological markers to predict risk of radiation injury. Semin Radiat Oncol 17: 89-98, 2007. (Pubitemid 46467379)
10. Müller K and Meineke V: Radiation-induced alterations in cytokine production by skin cells. Exp Hematol 35(4 Suppl 1): 96-104, 2007. (Pubitemid 46427987)
11. Kovacs CJ, Daly BM, Evans MJ, Johnke RM, Lee TK, Karlsson UL, Allison R, Eaves GS and Biggs LM: Cytokine profiles in patients receiving wide-field + prostate boost radiotherapy (xRT) for adenocarcinoma of the prostate. Cytokine 23: 151-163, 2003..
12. Lawton CA, Winter K, Byhardt R, Sause WT, Hanks GE, Russell AH, Rotman M, Porter A, McGowan DG, DelRowe JD and Pilepich MV: Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 38: 931-939, 1997.
13. Zietman AL, Prince EA, Nakfoor BM and Shipley WU: Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results. Urology 49(3A Suppl): 74-83, 1997.
14. Roach M 3rd: Neoadjuvant therapy prior to radiotherapy for clinically localized prostate cancer. Eur Urol 32(Suppl 3): 48-54, 1997.
15. Zietman AL: The case for neoadjuvant androgen suppression before radiation therapy. MoI Urol 4: 203-208, 2000. (Pubitemid 30808873)
16. DeWeese TL and Song DY: Current evidence for the role of combined androgen suppression and radiation in the treatment of adenocarcinoma of the prostate. Urology 55: 169-174, 2000.
17. McLeod DG and Moul JW: Controversies in the treatment of prostate cancer with maximal androgen deprivation. Surg Oncol Clin N Am 4: 345-359, 1995.
18. Harle LK, Maggio M, Shahani S, Braga-Basaria M and Basaria S: Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin Adv Hematol Oncol 4: 687-696, 2006. (Pubitemid 44560316)
19. Basaria S, Lieb J 2nd, Tang AM, DeWeese T, Carducci M, Eisenberger M and Dobs AS: Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 56: 779-786, 2002.
20. Ablin RJ, Bartkus JM and Gonder MJ: In vitro effects of diethylstilbestrol and the LHRH analogue leuprolide on natural killer cell activity. Immunopharmacology 15: 95-101, 1998.
21. Ablin RJ, Bhatti RA and Guinan PD: Effect of estrogen on tumor-associated immunity in patients with adenocarcinoma of the prostate. Cancer Res 38: 3702-3706, 1978. (Pubitemid 9045193)
22. Ablin RJ, Gonder MJ and Bartkus JM: Leuprolide vs. diethylstilboestrol: effect on natural killer cells. Anticancer Res 8: 73-76, 1988.
23. Khosla S, Atkinson EJ, Dunstan CR and O'Fallon WM: Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 87: 1550-1554, 2002.
24. Maggio M, Blackford A, Taub D, Carducci M, Ble A, Metter EJ, Braga-Basaria M, Dobs A and Basaria S: Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy. J Androl 27: 725-728, 2006. (Pubitemid 44846010)
25. Johnke RM, Edwards JM, Kovacs CJ, Evans MJ, Daly BM, Karlsson UL, Lee TK, Allison RR, Arastu HH, Cariveau MJ and O'Brien KF: Response of T lymphocyte populations in prostate cancer patients undergoing radiotherapy: influence of neoajuvant total androgen suppression. Anticancer Res 25: 3159-3166, 2005.
26. Bensalah K, Lotan Y, Karam JA and Shariat SF: New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis 11: 112-120, 2008. (Pubitemid 351676597)
27. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT and Thompson TC: Elevated levels of circulating interleukin-6 and transforming growth factor-betal in patients with metastatic prostatic carcinoma. J Urol 161: 182-187, 1999. (Pubitemid 29422316)
28. 1 as a biomarker for prostate cancer. J Cell Biochem 16H(Suppl): 54-61, 1992. (Pubitemid 23047970)
29. 1 with prostate cancer: an immunohistochemical study. Hum Pathol 24: 4-9, 1993. (Pubitemid 23046665)
30. Shariat SF, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM and Slawin KM: Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 10: 1992-1999, 2004.
31. Ivanovic V, Melman A, Davis-Joseph B, Valcic M and Geliebter J: Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. Nat Med 1: 282-284, 1995.
32. Perry KT, Anthony CT, Case T and Steiner MS: Transforming growth factor beta as a clinical biomarker for prostate cancer. Urology 49: 151-155, 1997. (Pubitemid 27043118)
33. Marchetti B, Guarcello V, Morale MC, Bartoloni G, Raiti F, Palumbo G Jr, Farinella Z, Cordaro S and Scapagnini U: Leutinizing hormone-releasing hormone (LHRH) agonist restoration of age-associated decline of thymus weight, thymic LHRH receptors, and thymocyte proliferative capacity. Endocrinology 125: 1037-1045, 1989. (Pubitemid 19205103)
34. McMurray RW, Suwannaroj S, Ndebele K and Jenkins JK: Differential effects of sex steroids on T and B cells: modulation of cell cycle phase distribution, apoptosis and bcl-2 protein levels. Pathobiology 69: 44-58, 2001. (Pubitemid 32973983)
35. Olsen NJ and Kovacs WJ: Effects of androgens on T and B lymphocyte development. Immunol Res 23: 281-288, 2001.
36. Olsen NJ and Kovacs WJ: Gonadal steroids and immunity. Endocr Rev 17: 369-384, 1996.
37. Olsen NJ, Viselli SM, Fan J and Kovacs WJ: Androgens accelerate thymocyte apoptosis. Endocrinology 139: 748-752, 1998.